MAFD9
MCID: MJR024
MIFTS: 40

Major Affective Disorder 9 (MAFD9)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 9

MalaCards integrated aliases for Major Affective Disorder 9:

Name: Major Affective Disorder 9 57 13 70
Major Affective Disorder-9, Susceptibility to 57
Bipolar Affective Disorder 57
Major Affective Disorder-9 57
Bipolar Disorder 70
Mafd9 57

Classifications:



External Ids:

OMIM® 57 612372
MedGen 41 C2700440
UMLS 70 C0005586 C2700440

Summaries for Major Affective Disorder 9

MalaCards based summary : Major Affective Disorder 9, also known as major affective disorder-9, susceptibility to, is related to major affective disorder 1 and bipolar disorder. An important gene associated with Major Affective Disorder 9 is MAFD9 (Major Affective Disorder-9, Susceptibility To). The drugs Eleuthero and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include cortex, brain and prefrontal cortex.

More information from OMIM: 612372

Related Diseases for Major Affective Disorder 9

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 major affective disorder 1 11.9
2 bipolar disorder 11.7
3 major affective disorder 5 11.6
4 major affective disorder 6 11.6
5 major affective disorder 8 11.5
6 major affective disorder 2 11.4
7 major affective disorder 3 11.4
8 major affective disorder 4 11.4
9 major affective disorder 7 11.4
10 mood disorder 10.8
11 schizophrenia 10.8
12 depression 10.7
13 endogenous depression 10.7
14 mental depression 10.7
15 bipolar i disorder 10.6
16 major depressive disorder 10.6
17 psychotic disorder 10.5
18 personality disorder 10.5
19 obsessive-compulsive disorder 10.5
20 schizoaffective disorder 10.5
21 alcohol dependence 10.4
22 tardive dyskinesia 10.4
23 hypothyroidism 10.4
24 substance abuse 10.4
25 borderline personality disorder 10.4
26 huntington disease 10.3
27 attention deficit-hyperactivity disorder 10.3
28 parkinsonism 10.3
29 cyclothymic disorder 10.3
30 anxiety 10.3
31 hydrocephalus 10.3
32 dementia 10.3
33 thalassemia 10.3
34 head injury 10.3
35 schizophrenia 1 10.2
36 frontotemporal dementia 10.2
37 mental health wellness 1 10.2
38 mental health wellness 2 10.2
39 alacrima, achalasia, and mental retardation syndrome 10.2
40 exanthem 10.2
41 physical disorder 10.2
42 thalassemia minor 10.2
43 movement disease 10.2
44 panic disorder 10.2
45 severe combined immunodeficiency 10.2
46 adenoma 10.2
47 hyperthyroidism 10.2
48 learning disability 10.2
49 substance dependence 10.2
50 darier-white disease 10.1

Comorbidity relations with Major Affective Disorder 9 via Phenotypic Disease Network (PDN):


Acute Cystitis Bipolar Disorder
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Major Affective Disorder 9:



Diseases related to Major Affective Disorder 9

Symptoms & Phenotypes for Major Affective Disorder 9

Clinical features from OMIM®:

612372 (Updated 05-Apr-2021)

Drugs & Therapeutics for Major Affective Disorder 9

Drugs for Major Affective Disorder 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Coal tar Approved Phase 4 8007-45-2
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Clozapine Approved Phase 4 5786-21-0 2818
7
Loxapine Approved Phase 4 1977-10-2 3964
8
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
9
Sertraline Approved Phase 4 79617-96-2 68617
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
12
Norepinephrine Approved Phase 4 51-41-2 439260
13
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
14
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
15
Topiramate Approved Phase 4 97240-79-4 5284627
16
Galantamine Approved Phase 4 357-70-0 9651
17
Memantine Approved, Investigational Phase 4 19982-08-2 4054
18
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
19
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
20
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
21
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
22
Oxcarbazepine Approved Phase 4 28721-07-5 34312
23
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
24
Nortriptyline Approved Phase 4 72-69-5 4543
25
Iloperidone Approved Phase 4 133454-47-4 71360
26
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
27
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
28
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
29
Ondansetron Approved Phase 4 99614-02-5 4595
30
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
31
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
32
Levetiracetam Approved Phase 4 102767-28-2 441341
33
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
34
Dipyridamole Approved Phase 4 58-32-2 3108
35
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
36
Atorvastatin Approved Phase 4 134523-00-5 60823
37
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
38
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
39
Metformin Approved Phase 4 657-24-9 4091 14219
40
Nicotine Approved Phase 4 54-11-5 942 89594
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
44
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
45
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
46
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
47
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Losartan Approved Phase 4 114798-26-4 3961
50
Lorazepam Approved Phase 4 846-49-1 3958

Interventional clinical trials:

(show top 50) (show all 1273)
# Name Status NCT ID Phase Drugs
1 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
2 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
3 Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder Unknown status NCT02478788 Phase 4 mixed amphetamine salts-extended release (MAS-XR);Placebo
4 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
5 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
6 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
7 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
8 A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder Unknown status NCT02562287 Phase 4 Clozapine;Risperidone;Olanzapine;Quetiapine
9 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
10 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
11 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
12 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
13 A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression Unknown status NCT02719392 Phase 4 Minocycline
14 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
15 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
16 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
17 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
18 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
19 Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics Completed NCT01811160 Phase 4 Melatonin;Placebo
20 A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Completed NCT01191918 Phase 4 Donepezil and Lithium;Placebo plus Lithium
21 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
22 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
23 Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181727 Phase 4 divalproex sodium extended release
24 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
25 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
26 A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting Completed NCT02525991 Phase 4
27 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
28 Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)
29 Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder Completed NCT00181935 Phase 4 risperidone (Risperdal);olanzapine (Zyprexa)
30 Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder Completed NCT00181883 Phase 4 quetiapine
31 Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
32 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
33 Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
34 Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking Completed NCT00621777 Phase 4 Varenicline;Placebo
35 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
36 A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide Completed NCT01416220 Phase 4 Lithium;Paroxetine
37 Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients Completed NCT02644577 Phase 4 Metformin
38 Acute Antidepressant Therapy in Bipolar II Major Depression Completed NCT00641927 Phase 4 Venlafaxine;Lithium Carbonate
39 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
40 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
41 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
42 An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode. Completed NCT00360126 Phase 4 lamotrigine
43 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
44 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging Completed NCT02473250 Phase 4 Fluoxetine;Citalopram
45 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
46 Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial Completed NCT00305370 Phase 4 Aripiprazole
47 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
48 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
49 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. Completed NCT00223249 Phase 4 Quetiapine
50 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole

Search NIH Clinical Center for Major Affective Disorder 9

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 9

Anatomical Context for Major Affective Disorder 9

MalaCards organs/tissues related to Major Affective Disorder 9:

40
Cortex, Brain, Prefrontal Cortex, Amygdala, Thyroid, Cingulate Cortex, Eye

Publications for Major Affective Disorder 9

Articles related to Major Affective Disorder 9:

(show top 50) (show all 27309)
# Title Authors PMID Year
1
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 57 61
18711365 2008
2
Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. 61
33515607 2021
3
Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. 61
33411248 2021
4
Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes. 61
33411239 2021
5
Treatment effect variability in brain stimulation across psychiatric disorders: A meta-analysis of variance. 61
33482243 2021
6
In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity. 61
32712907 2021
7
Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. 61
33577882 2021
8
Clinical Predictors of Non-Response to Lithium Treatment in The Pharmacogenomics of Bipolar Disorder (PGBD) Study. 61
33797828 2021
9
Risk factors for natural cause mortality in a cohort of 1494 persons with serious mental illness. 61
33578064 2021
10
Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders. 61
31712721 2021
11
Performance on the Wechsler Adult Intelligence Scale (WAIS) in Japanese patients with bipolar and major depressive disorders in euthymic and depressed states. 61
33368739 2021
12
Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. 61
33387333 2021
13
Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. 61
33595954 2021
14
Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression. 61
33127073 2021
15
Transdiagnostic comparison of visual working memory capacity in bipolar disorder and schizophrenia. 61
33797645 2021
16
Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder. 61
33636995 2021
17
Lakshmi Yatham: unravelling the biology of bipolar disorder. 61
33743880 2021
18
Genetic neuroimaging of bipolar disorder: a systematic 2017-2020 update. 61
33492063 2021
19
Differential diagnosis of borderline personality disorder and bipolar disorder: self-concept, identity and self-esteem. 61
33811707 2021
20
Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. 61
33618245 2021
21
Changes in Intrinsic Brain Connectivity in Family-Focused Therapy Versus Standard Psychoeducation Among Youths at High Risk for Bipolar Disorder. 61
32745598 2021
22
The association between self-reported physical activity and objective measures of physical activity in participants with newly diagnosed bipolar disorder, unaffected relatives, and healthy individuals. 61
33779478 2021
23
Manic morbidity and executive function impairment as determinants of long-term psychosocial dysfunction in bipolar disorder. 61
33792890 2021
24
Brain activation during verbal fluency task in type II bipolar disorder patients: a near-infrared spectroscopy study. 61
33545426 2021
25
Preventive effect of morning light exposure on relapse into depressive episode in bipolar disorder. 61
33587769 2021
26
The functional polymorphisms linked with interleukin-1β gene expression are associated with bipolar disorder. 61
33707400 2021
27
N-acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: A pilot study. 61
33797205 2021
28
Analysis of functional MRI signal complexity based on permutation fuzzy entropy in bipolar disorder. 61
33657075 2021
29
ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization. 61
31993746 2021
30
Lived Experiences of a Sustained Mental Health Recovery Process Without Ongoing Medication Use. 61
32696208 2021
31
Use of social media and online dating among individuals with a history of affective disorder. 61
33054870 2021
32
A meta-study on transcription factor networks in the suicidal brain. 61
33548827 2021
33
Aripiprazole and lactation failure: The importance of shared decision making. A case report. 61
33796446 2021
34
Clinical characteristics of bipolar disorders with postpartum depressive onset. 61
33347983 2021
35
Emotion regulation in pediatric bipolar disorder: A meta-analysis of published studies. 61
33639359 2021
36
A nationwide population-based longitudinal study mapping psychiatric disorders during lifetime in siblings to patients with bipolar disorder. 61
33258104 2021
37
Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. 61
31397223 2021
38
Cancer Screening Among Adults With and Without Serious Mental Illness: A Mixed Methods Study. 61
33704103 2021
39
Validation of the Yale Food Addiction Scale 2.0 in Patients Seeking Bariatric Surgery. 61
33405178 2021
40
Trends in Trimorbidity Among Adults Experiencing Homelessness in Minnesota, 2000-2018. 61
33710099 2021
41
Gut microbiota-derived vitamins - underrated powers of a multipotent ally in psychiatric health and disease. 61
33428888 2021
42
Neuroprotective Effect of Intravitreal Single-Dose Lithium Chloride after Optic Nerve Injury in Rats. 61
32885675 2021
43
Multimodal imaging improves brain age prediction and reveals distinct abnormalities in patients with psychiatric and neurological disorders. 61
33340180 2021
44
How and Why Are Irritability and Depression Linked? 61
33743947 2021
45
Does maternal race or ethnicity modify the association between maternal psychiatric disorders and preterm birth? 61
33393465 2021
46
The role of brain barriers in the neurokinetics and pharmacodynamics of lithium. 61
33549730 2021
47
Internet of things issues related to psychiatry. 61
33797634 2021
48
Patterns of Mental Health Care Before Initiation of Telemental Health Services. 61
33797510 2021
49
Using additive and relative hazards to quantify colorectal survival inequalities for patients with a severe psychiatric illness. 61
33239182 2021
50
25 Years of the International Bipolar Collaborative Network (BCN). 61
33811284 2021

Variations for Major Affective Disorder 9

Expression for Major Affective Disorder 9

Search GEO for disease gene expression data for Major Affective Disorder 9.

Pathways for Major Affective Disorder 9

GO Terms for Major Affective Disorder 9

Sources for Major Affective Disorder 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....